Core Viewpoint - Sino Medical announced that its subsidiary, Sino Shenchang Medical Technology Co., Ltd., received the Medical Device Registration Certificate from the National Medical Products Administration of China for a flow-directed mesh stent designed for adult patients with unruptured wide-neck aneurysms in the internal carotid and vertebral arteries [1] Group 1 - The product is the first domestically available flow-directed mesh stent that can be delivered through a 0.017'' system and features an anti-thrombotic coating [1] - This product fills a gap in the company's existing offerings in the neurointerventional hemorrhage field, enhancing the company's product portfolio [1] - The introduction of this stent meets diverse market demands and further enriches the company's product lineup [1]

Core Viewpoint - The news highlights recent stock trading activities by the director of Sino Medical, Cai Wenbin, including a reduction in shareholding and the company's financial performance in the medical device sector [1][2]. Group 1: Stock Trading Activities - On May 20, 2025, Cai Wenbin sold 20,000 shares at an average price of 9.91 yuan, resulting in a transaction amount of 198,200 yuan, leaving him with 136,000 shares [1]. - Cai Wenbin's previous transactions include selling 4,000 shares on May 13, 2025, at 10 yuan, and multiple other trades in early May 2025, indicating a pattern of selling shares in the secondary market [2]. Group 2: Company Overview and Financial Performance - Sino Medical's main business includes the production and operation of Class II and Class III medical devices, along with various technical services and equipment leasing [2]. - As of December 31, 2024, the company's revenue from stents was 261 million yuan, accounting for 56.87% of total revenue, while balloon revenue was 181 million yuan, making up 39.51% [2]. - The total market capitalization of Sino Medical is reported to be 4.11 billion yuan [2].

Meeting Overview - The shareholders' meeting of Sino Medical Science Technology Co., Ltd. was held on May 19, 2025, at the company's conference room in Beijing [1][2] - A total of 60 ordinary shareholders attended the meeting, holding 102,576,238 voting rights, which represents 24.81% of the company's total voting rights [2] Voting Process - The meeting was chaired by the company's chairman, Mr. Sun Jianhua, and followed the voting procedures as per the Company Law and the company's articles of association [2][7] - The voting method combined on-site and online voting, with legal representatives present to witness the proceedings [2][7] Voting Results - All proposed resolutions were approved with significant majority support, including: - 99.87% of ordinary shareholders voted in favor of the resolutions, with only 0.12% against and 0.004% abstaining [3][5] - Specific resolutions included the remuneration plan for the supervisors and the reappointment of auditors, both of which received over 99% approval [6][7] Legal Compliance - The lawyers present confirmed that the meeting's procedures complied with relevant laws and regulations, ensuring the legitimacy of the attendees and the voting process [7]

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-025 赛诺医疗科学技术股份有限公司 2024年年度股东大会决议公告 数量的情况： | 1、出席会议的股东和代理人人数 | 60 | | --- | --- | | 普通股股东人数 | 60 | | 2、出席会议的股东所持有的表决权数量 | 102,576,238 | | 普通股股东所持有表决权数量 | 102,576,238 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 24.8095 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 24.8095 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长孙箭华先生主持召开。本次股东大会采用现场投 票和网络投票相结合的方式表决。公司聘请了上海市锦天城（北京）律师事务所梁文盛律师、 梁睿律师对本次股东大会进行见证。本次股东大会的召集、召开程序、出席会议人员的资格和 召集人资格、会议的表决程序和表决结果均符合《公司法》及《赛诺医疗科学技术股份有限公 司章程》等的规定。 本公司董事会及全体董事保证公 ...

上海市锦天城（北京）律师事务所 关于赛诺医疗科学技术股份有限公司 2024 年年度股东大会之 法 律 意 见 书 城 律师事 ALLBRIGHT LAW OFFICES 北京市 东城区 东长安街1号 东方广场C1座6层(100738) 6/F,Office Tower C1,Oriental Plaza,No.1 East Chang An Avenue,Beijing 100738,PRC Tel: +86 10 8523 0688 Fax: +86 10 8523 0699 www.allbrightlaw.com 法律意见书 上海市锦天城（北京）律师事务所 关于赛诺医疗科学技术股份有限公司 2024 年年度股东大会之 法律意见书 致:赛诺医疗科学技术股份有限公司 根据《中华人民共和国证券法》(以下简称"《证券法》")、《中华人民 共和国公司法》(以下简称"《公司法》")和中国证券监督管理委员会《上市 公司股东会规则》(以下简称"《股东会规则》")等法律、行政法规、规章和 规范性文件的要求以及《赛诺医疗科学技术股份有限公司章程》(以下简称"《公 司章程》"),上海市锦天城(北京)律师事务所(以下简称"本所 ...

Group 1 - The 2025 Oriental Cerebrovascular Disease Conference showcased clinical trial data for the self-expanding intracranial drug-eluting stent by Sino Medical, highlighting its low restenosis rates [2][4] - The 1-year restenosis rate for the Sino Medical stent was reported at only 1.87%, significantly lower than the average restenosis rate of 14.8% for existing intracranial stents [2] - Intracranial artery stenosis is a major cause of stroke in Asian populations, with a high prevalence compared to Western countries, indicating a substantial unmet medical need [2] Group 2 - The new coated flow-diverting stent demonstrated a 1-year aneurysm occlusion rate of 96.99%, the highest among similar products [3] - The stent achieved a 6-month occlusion rate of 89.78%, outperforming competitors that require a full year to reach similar results [3] - The safety composite endpoint for the new stent was reported at 1.4%, the lowest among comparable products, indicating a significant advancement in safety [3] Group 3 - The aging population is driving a rapid increase in the demand for cardiovascular disease treatments, with domestic innovations in neurointerventional devices opening new avenues for safety and efficacy [4] - Sino Medical's intracranial self-expanding drug-eluting stent system has received approval from the National Medical Products Administration and is undergoing registration in Europe and domestically [4] - The new coated flow-diverting stent is also in the registration approval process, reflecting ongoing advancements in the field [4]

Core Viewpoint - The article discusses the increasing number of accounting errors among listed companies, with over 40 companies correcting such errors in 2025, highlighting the potential risks and implications for investors [1] Group 1: Accounting Errors and Company Responses - Accounting errors are defined as unintentional omissions or misstatements in financial reports, contrasting with accounting fraud, which is intentional [1] - Companies like Sainuo Medical have recently disclosed accounting errors, including a miscalculation of equity stakes leading to significant adjustments in financial statements [2][3] - Sainuo Medical's adjustments included a reduction in investment income by 9.59 million yuan and a decrease in net profit attributable to shareholders by 4.17 million yuan, among other corrections [3][4] Group 2: Financial Performance and Market Dynamics - Sainuo Medical's revenue has shown volatility, with a drop from 300 million yuan in 2020 to below 200 million yuan in 2021 and 2022, followed by a rebound in 2023 and continued growth in 2024 [9][11] - The company's main products, coronary stents and balloons, accounted for 56.97% and 39.58% of total revenue, respectively, indicating a reliance on these core products [9] - The impact of centralized procurement policies on Sainuo Medical's sales has been significant, with a notable decline in market share during the first round of procurement [11] Group 3: Management and Governance Issues - The company has faced scrutiny regarding its internal controls and the effectiveness of its financial oversight, particularly in light of repeated accounting errors [6][7] - Sainuo Medical's management has been criticized for inconsistent judgments regarding accounting errors, raising questions about the company's financial practices [6][7] - Recent insider selling by multiple executives, including core technical personnel, has raised concerns about management confidence in the company's future performance [16]

Core Viewpoint - Sino Medical Science and Technology Co., Ltd. has received registration certificates for its SC HONKYTONK™ coronary balloon dilation catheter and NC ROCKSTAR™ non-compliant balloon dilation catheter from COFEPRIS and ARCSA, marking a significant step in the company's overseas business expansion [1][2][3] Product Registration Details - The SC HONKYTONK™ coronary balloon dilation catheter is designed for rapid exchange and is composed of multiple components including a tip, balloon protective sheath, and a platinum-iridium alloy radiopaque marker. It is sterilized with ethylene oxide and has a shelf life of 3 years [1][2] - The NC ROCKSTAR™ non-compliant balloon dilation catheter features a dual-layer balloon design that balances high burst pressure and low compliance, ensuring better tracking performance and resistance to kinking during procedures. It is also sterilized with ethylene oxide and has a shelf life of 3 years [2][3] Market and Regulatory Approvals - Both products have received various international certifications, including the China National Medical Products Administration (NMPA) registration in December 2022, and are expected to receive FDA approval and other international registrations from 2022 to 2025 [2][3] - The SC HONKYTONK™ catheter has been approved in multiple countries including the USA, Thailand, Taiwan, India, Uzbekistan, Pakistan, South Korea, Hong Kong, Belarus, Kyrgyzstan, Morocco, Peru, Malaysia, Mexico, and Ecuador [2][3] Impact on Company - The acquisition of these registration certificates is expected to enhance the sales of the company's products in international markets, contributing positively to the company's overseas business growth [3]

证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 赛诺医疗科学技术股份有限公司 为保障赛诺医疗科学技术股份有限公司（以下简称"公司"）全体股东的合法权益，维护 股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大会如期、顺利召开，根据《中 华人民共和国公司法》 《赛诺医疗科学技术股份有限公司章程》 《赛诺医疗科学技术股份有限公 司股东大会议事规则》及中国证监会、上海证券交易所的有关规定，特制定本须知。 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工作。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东及股东代理人的合法权益， 除出席会议的股东及股东代理人、公司董事、监事、高级管理人员、见证律师及董事会邀请的 人员外，公司有权依法拒绝其他人员进入会场。 三、出席现场会议的股东及股东代理人须在会议召开前半小时到达会议现场办理签到手续， 并请按规定出示证券账户卡、身份证明文件或营业执照/注册证书复印件（加盖公章）、授权委 托书以及参会回执等，上述登记材料均需要提供复印件一份，个人登记材料复印件须个人签字， 法定代表人证明文件复印件须公司盖章，经验证后领取会议资料 ...

赛诺医疗科学技术股份有限公司 证券代码：688108 证券简称：赛诺医疗 公告编号：2025-024 关于公司产品在海外获得注册证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于 2023 年 05 月和 2024 年 11 月分别向墨西哥的国家卫生监管局（COFEPRIS）和厄瓜多尔国家卫生监管局 （ARCSA）递交了公司 SC HONKYTONKTM 冠脉球囊扩张导管和 NC ROCKSTAR TM非顺应 性球囊扩张导管的注册申报资料。公司于近日收到 COFEPRIS 和 ARCSA 的通知，公司 SC HONKYTONKTM 冠脉球囊扩张导管和 NC ROCKSTARTM非顺应性球囊扩张导管的注册申报 资料获得 COFEPRIS 的批准。现将相关情况公告如下： 一、注册证内容 1、SC HONKYTONKTM 冠脉球囊扩张导管 证书编号：COFEPRIS -- 0753C2025 SSA；ARCSA-- 18556-DME-0425 产 ...